Correlation between lymphoma and second primary malignant tumor

Area of Science:

• Oncology
• Epidemiology
• Cancer Research

Background:

• Limited research exists on secondary primary malignancies (SPMs) in lymphoma survivors, particularly regarding risk factors and comparative survival.
• Understanding SPM development is crucial for improving long-term outcomes in lymphoma patients.

Purpose of the Study:

• To evaluate the cumulative incidence and risk factors of SPMs in lymphoma patients.
• To compare the survival rates of SPMs versus matched primary malignant tumors.

Main Methods:

• Retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) database (2000-2019).
• Analysis included Fine-Gray competing risk regression for cumulative incidence, Poisson regression for risk factors, and Kaplan-Meier analysis for survival.
• Propensity score matching was used for survival comparisons.

Main Results:

• The cumulative incidence of SPMs over 20 years was 1.95% (respiratory), 0.14% (CNS), 0.82% (hepatobiliary), 1.31% (urinary), and 1.92% (digestive).
• Lymphoma patient characteristics, radiotherapy, chemotherapy, diagnosis time, age, and incubation period influenced SPM risk.
• Secondary SPMs had significantly lower survival rates than matched primary malignant tumors.

Conclusions:

• Lymphoma patients have a notable risk of developing SPMs, influenced by various factors.
• Early consideration of SPM risk and personalized follow-up strategies are essential for lymphoma survivors.
• Improved surveillance can mitigate the impact of SPMs and enhance patient survival outcomes.